Fusion Pharmaceuticals Inc.
Fusion Pharmaceuticals Inc.（FUSN）股东结构
基于 13F 申报与流通股数据，展示机构、内部人与公众持股结构；下方为前十大机构、机构动向与内部人交易。
SEC 13F · FMP · FUSN · 截至 2024年3月31日
股东结构概览
140
机构持有人数
▲ 57 vs Q4
$1.47B
机构持仓总市值
▲ $888.91M vs Q4
85.06M
总流通股
freeFloat 72.39%
69.09M
13F 申报持股数
▲ 8.29M vs Q4
机构持仓% = 13F 持股数 ÷ 总流通股。内部人% = 100 − 自由流通率。散户% = 自由流通率 − 机构%。数据来源：FMP /symbol-positions-summary + /shares-float + SEC EDGAR。
前10大机构持仓
FUSN 最大股东 · 机构持仓
Q1 2024 · SEC 13F
显示前 10 家
| 机构 | 持股数 | 占比 | 权重 | 市值 | 申报日 | 变动 |
|---|---|---|---|---|---|---|
FEDERATED HERMES, INC. biological products, (no diagnostic substances) | 10.81M | 14.79% | 14.79% | $230.49B | May 14, 2024 | ▼ 75.0K |
PERCEPTIVE ADVISORS LLC biological products, (no diagnostic substances) | 6.83M | 9.34% | 9.34% | $145.52B | Aug 6, 2024 | ▲ 4.07M |
AVIDITY PARTNERS MANAGEMENT LP biological products, (no diagnostic substances) | 6.50M | 8.89% | 8.89% | $138.59B | May 15, 2024 | — held |
DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) biological products, (no diagnostic substances) | 6.40M | 8.76% | 8.76% | $136.47B | May 15, 2024 | — held |
FIL LTD biological products, (no diagnostic substances) | 4.19M | 5.73% | 5.73% | $89.27B | May 13, 2024 | NEW |
PENTWATER CAPITAL MANAGEMENT LP biological products, (no diagnostic substances) | 3.78M | 5.17% | 5.17% | $80.63B | May 15, 2024 | NEW |
JOHNSON & JOHNSON biological products, (no diagnostic substances) | 3.67M | 5.02% | 5.02% | $78.26B | May 10, 2024 | — held |
CANADA PENSION PLAN INVESTMENT BOARD biological products, (no diagnostic substances) | 3.12M | 4.26% | 4.26% | $66.45B | May 14, 2024 | — held |
TPG GP A, LLC biological products, (no diagnostic substances) | 2.55M | 3.49% | 3.49% | $54.40B | Aug 14, 2024 | — held |
FMR LLC biological products, (no diagnostic substances) | 1.84M | 2.51% | 2.51% | $39.16B | May 13, 2024 | ▼ 3.48M |
数据来源：SEC 13F 申报文件。变动标识：isNew / isSoldOut / changeInSharesNumber。
机构仓位变动
Q1 2024 对比上季度
Q1 2024
14
增持
+9.28M 股22
新建仓
首次建仓7
减持
−5.55M 股0
清仓
完全退出净股数变化（前50家）
+3.73M
+9.28M / −5.55M
净新增持仓人
+29
新建 22 个 / 退出 0 个
基于前50家最大机构持仓统计，全市场实际数量可能不同。
内幕交易买卖情绪
FUSN 内幕交易记录
数据来源：SEC Form 4
0
买入笔数
69
卖出笔数
0.00
买卖比
$9M
卖出总金额
最近内幕交易记录
最近10条 · 仅普通股
| 姓名 · 职位 | 日期 | 类型 | 股数 | 价格 | 金额 | 交易后持股 | 申报 |
|---|---|---|---|---|---|---|---|
Bitetti Teresa Marie director | Jun 4, 2024 | D-Return | 34,000 | $4.16 | $141.4K | 0 | Form 4 ↗ |
GANNON STEVEN director | Jun 4, 2024 | D-Return | 56,400 | $21.00 | $1.18M | 0 | Form 4 ↗ |
GANNON STEVEN director | Jun 4, 2024 | D-Return | 17,000 | $3.60 | $61.2K | 0 | Form 4 ↗ |
GANNON STEVEN director | Jun 4, 2024 | D-Return | 17,000 | $4.64 | $78.9K | 0 | Form 4 ↗ |
GANNON STEVEN director | Jun 4, 2024 | D-Return | 17,000 | $8.15 | $138.6K | 0 | Form 4 ↗ |
GANNON STEVEN director | Jun 4, 2024 | D-Return | 141,011 | $2.35 | $331.4K | 0 | Form 4 ↗ |
GANNON STEVEN director | Jun 4, 2024 | D-Return | 30,000 | $17.00 | $510.0K | 0 | Form 4 ↗ |
Valliant John Chief Executive Officer | Jun 4, 2024 | D-Return | 192,200 | — | — | 0 | Form 4 ↗ |
Valliant John Chief Executive Officer | Jun 4, 2024 | D-Return | 336,000 | $11.90 | $4.00M | 0 | Form 4 ↗ |
Valliant John Chief Executive Officer | Jun 4, 2024 | D-Return | 500,000 | $3.75 | $1.88M | 0 | Form 4 ↗ |
数据来源：SEC Form 4。买卖方向：acquisitionOrDisposition A=买入，D=卖出。已排除 RSU 归属（M-Exempt）。
关于机构与内部人持股结构
Fusion Pharmaceuticals Inc.（FUSN）主要由机构投资者持有，机构持股比例约为 81.2%。公司内部人员持股约 27.61%，散户及公众持股约占剩余的 0.00%。
Fusion Pharmaceuticals Inc. 最大机构股东为 FEDERATED HERMES, INC.，截至 March 31, 2024 持有约 10.81 million 股，占总流通股的 14.79%。
目前共有 140 家机构持有 FUSN 股票，合计持仓市值约 $1.47 billion，数据来源为最新 SEC 13F 申报。
常见问题
FUSN ownershipFusion Pharmaceuticals Inc.（FUSN）主要由机构投资者持有，机构持股约 81.2%。最大股东为 FEDERATED HERMES, INC.，持股比例 14.79%。内部人员持股约 27.61%。数据来源 SEC Form 13F，截至 March 31, 2024。